These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38487332)

  • 1. Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report.
    Mariottini A; Barilaro A; Lotti A; Marra F; Massacesi L
    Front Neurol; 2024; 15():1363493. PubMed ID: 38487332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.
    Torres JB; Roodselaar J; Sealey M; Ziehn M; Bigaud M; Kneuer R; Leppert D; Weckbecker G; Cornelissen B; Anthony DC
    Front Immunol; 2022; 13():814064. PubMed ID: 35967378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system.
    Scavone C; Anatriello A; Baccari I; Cantone A; Di Giulio Cesare D; Bernardi FF; Moreggia O; Liguori V; Andreone V; Maniscalco GT; Capuano A
    Front Neurol; 2024; 15():1383910. PubMed ID: 38994488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
    Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
    Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.
    Ciardi MR; Iannetta M; Zingaropoli MA; Salpini R; Aragri M; Annecca R; Pontecorvo S; Altieri M; Russo G; Svicher V; Mastroianni CM; Vullo V
    Open Forum Infect Dis; 2019 Jan; 6(1):ofy356. PubMed ID: 30697576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab.
    Craner M; Al Malik Y; Babtain FA; Alshamrani F; Alkhawajah MM; Alfugham N; Al-Yafeai RH; Aljarallah S; Makkawi S; Qureshi S; Ziehn M; Wahba H
    Neurol Ther; 2022 Dec; 11(4):1457-1473. PubMed ID: 36048334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
    Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
    Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.
    Florou D; Katsara M; Feehan J; Dardiotis E; Apostolopoulos V
    Brain Sci; 2020 Oct; 10(10):. PubMed ID: 33092190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
    Sorensen PS; Blinkenberg M
    Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
    Pukoli D; Vécsei L
    Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
    Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
    Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
    Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
    J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
    [No Abstract]   [Full Text] [Related]  

  • 16. Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review.
    Usman S; Cheema M; Ghuman Z; Mustafa S; Iftikhar A
    Arch Clin Cases; 2024; 11(2):69-73. PubMed ID: 39015300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab for relapsing forms of multiple sclerosis.
    Gajofatto A; Orlandi R
    Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab: A Review in Multiple Sclerosis.
    Lamb YN
    Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.